Search

Displaying results 5911 - 5920 of 9702 in total
  1. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the

  2. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    Darvadstrocel is a suspension of expanded human allogeneic adipose-derived mesenchymal stem cells extracted from the subdermal adipose tissue of healthy donors via liposuction. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  3. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237505] TBE often manifests in a biphasic manner, with patients experiencing a flu-like illness followed by a variable asymptomatic period and then a second phase characterized by various neurological … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.

  4. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (
  5. Drug

    Orticumab

    go.drugbank.com/drugs/DB16653
    Investigational

    Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).

  6. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    episodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  7. Drug

    Oxelumab

    go.drugbank.com/drugs/DB16663
    Investigational

    Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

  8. Drug

    Torudokimab

    go.drugbank.com/drugs/DB16671
    Investigational

    Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).

  9. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).

  10. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells.